Carla Kim headshot

Carla Kim, Ph.D.

Principal Investigator, Boston Children’s Hospital
Stem Cell Program Faculty, Stem Cell Program
Professor of Genetics and Pediatrics, Harvard Medical School
617-919-4644
Kim Lab Website

The broad interest of the Kim Lab is to characterize the biology of stem cells in normal lung and lung cancer. Numerous lung diseases such as cystic fibrosis or chronic obstructive pulmonary disease involve injured or depleted bronchiolar or alveolar epithelium. Bronchiolar and alveolar cells are also affected in adenocarcinoma, the most common form of lung cancer. It is likely that lung stem cells are critically affected in patients with these devastating diseases. Our long-term goal is to elucidate the role of stem cells in lung homeostasis as a prerequisite to the development of therapeutic strategies that can be used to prevent or attenuate lung disease.

Please see our website for more information: https://www.childrenshospital.org/research/labs/kim-laboratory

Intersections of lung progenitor cells, lung disease and lung cancer.
Authors: Authors: Kim CF.
Eur Respir Rev
View full abstract on Pubmed
Erratum: Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2.
Authors: Authors: Zhang H, Brainson CF, Koyama S, Redig AJ, Chen T, Li S, Gupta M, Garcia-de-Alba C, Paschini M, Herter-Sprie GS, Lu G, Zhang X, Marsh BP, Tuminello SJ, Xu C, Chen Z, Wang X, Akbay EA, Zheng M, Palakurthi S, Sholl LM, Rustgi AK, Kwiatkowski DJ, Alan Diehl J, Bass AJ, Sharpless NE, Dranoff G, Hammerman PS, Ji H, Bardeesy N, Saur D, Watanabe H, Kim CF, Wong KK.
Nat Commun
View full abstract on Pubmed
Don't Stop Re-healin'! Cancer as an Ongoing Stem Cell Affair.
Authors: Authors: Rowbotham SP, Kim CF.
Cell
View full abstract on Pubmed
Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2.
Authors: Authors: Zhang H, Fillmore Brainson C, Koyama S, Redig AJ, Chen T, Li S, Gupta M, Garcia-de-Alba C, Paschini M, Herter-Sprie GS, Lu G, Zhang X, Marsh BP, Tuminello SJ, Xu C, Chen Z, Wang X, Akbay EA, Zheng M, Palakurthi S, Sholl LM, Rustgi AK, Kwiatkowski DJ, Diehl JA, Bass AJ, Sharpless NE, Dranoff G, Hammerman PS, Ji H, Bardeesy N, Saur D, Watanabe H, Kim CF, Wong KK.
Nat Commun
View full abstract on Pubmed
Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer.
Authors: Authors: Zhang H, Qi J, Reyes JM, Li L, Rao PK, Li F, Lin CY, Perry JA, Lawlor MA, Federation A, De Raedt T, Li YY, Liu Y, Duarte MA, Zhang Y, Herter-Sprie GS, Kikuchi E, Carretero J, Perou CM, Reibel JB, Paulk J, Bronson RT, Watanabe H, Brainson CF, Kim CF, Hammerman PS, Brown M, Cichowski K, Long H, Bradner JE, Wong KK.
Cancer Discov
View full abstract on Pubmed
EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors.
Authors: Authors: Fillmore CM, Xu C, Desai PT, Berry JM, Rowbotham SP, Lin YJ, Zhang H, Marquez VE, Hammerman PS, Wong KK, Kim CF.
Nature
View full abstract on Pubmed
Tracing the potential of lung progenitors.
Authors: Authors: Mahoney JE, Kim CF.
Nat Biotechnol
View full abstract on Pubmed
Developmental biology. Mesenchymal progenitor panoply.
Authors: Authors: Lee JH, Kim CF.
Science
View full abstract on Pubmed
Non-small-cell lung cancers: a heterogeneous set of diseases.
Authors: Authors: Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK.
Nat Rev Cancer
View full abstract on Pubmed
Neurotrophin receptor TrkB promotes lung adenocarcinoma metastasis.
Authors: Authors: Sinkevicius KW, Kriegel C, Bellaria KJ, Lee J, Lau AN, Leeman KT, Zhou P, Beede AM, Fillmore CM, Caswell D, Barrios J, Wong KK, Sholl LM, Schlaeger TM, Bronson RT, Chirieac LR, Winslow MM, Haigis MC, Kim CF.
Proc Natl Acad Sci U S A
View full abstract on Pubmed